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The choroid plexus epithelium (CPE) secretes higher volumes of fluid (cerebrospinal fluid, CSF) than any other epithelium and simultaneously functions as the blood-CSF barrier to gate immune cell entry into the central nervous system 1 . Posthemorrhagic hydrocephalus (PHH), an expansion of the cerebral ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a common disease usually treated by suboptimal CSF shunting techniques 2 . PHH is classically attributed to primary impairments in CSF reabsorption, but little experimental evidence supports this concept. In contrast, the potential contribution of CSF secretion to PHH has received little attention. In a rat model of PHH, we demonstrate that IVH causes a Toll-like receptor 4 (TLR4)-and NF-kB-dependent inflammatory response in the CPE that is associated with a ~3-fold increase in bumetanide-sensitive CSF secretion. IVH-induced hypersecretion of CSF is mediated by TLR4-dependent activation of the Ste20-type stress kinase SPAK, which binds, phosphorylates, and stimulates the NKCC1 co-transporter at the CPE apical membrane. Genetic depletion of TLR4 or SPAK normalizes hyperactive CSF secretion rates and reduces PHH symptoms, as does treatment with drugs that antagonize TLR4-NF-kB signaling or the SPAK-NKCC1 co-transporter complex. These data uncover a previously unrecognized contribution of CSF hypersecretion to the pathogenesis of PHH, demonstrate a new role for TLRs in regulation of the internal brain milieu, and identify a kinaseregulated mechanism of CSF secretion that could be targeted by repurposed US Food and Drug Administration (FDA)-approved drugs to treat hydrocephalus.
IVH frequently leads to PHH, resulting in worse outcomes for germinal matrix and subarachnoid bleeds, and for intraparenchymal hemorrhage 2 . The elevated intracranial pressure (ICP) in PHH damages periventricular white matter, impairing brain development in children and causing neurodegeneration in adults 3 . Severe, persistent elevations in ICP can cause acute brainstem herniation and death. Invasive CSF shunting, an empirical 'one-size-fits-all' approach with high morbidity due to frequent shunt obstructions and infections requiring surgical revision 2 , remains the mainstay of PHH treatment. Targeted pharmacotherapeutic strategies constitute an urgent, unmet need for patients of all ages with hydrocephalus 3 .
It is widely accepted that PHH results from intraventricular CSF accumulation due to failed homeostasis mechanisms. Classical models of CSF dynamics hold that PHH results from a primary decrease in CSF reabsorption due to obstruction of intraventricular CSF flow and/or dysfunction of extraventricular arachnoid granulations; however, this paradigm is supported by sparse experimental evidence 4 , and it neglects the potential roles of increased CSF secretion in disease pathogenesis 5 . Although intracerebroventricular (ICV) injection of IVH-derived metabolites is sufficient to cause CPE inflammation 6 and hydrocephalus in both humans and animal systems 7 , the molecular mechanisms through which IVH leads to ventriculomegaly remain incompletely understood.
Systemic secretory epithelia can respond to proinflammatory stimuli by increasing their rate of fluid secretion 8 . Initially, this secretory response may be adaptive in maintaining homeostasis by clearing pathogenic organisms or debris from the epithelial surface 9, 10 . However, sustained inflammation can be maladaptive and create Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus disease vulnerabilities 11, 12 , and dysregulated epithelial homeostasis can result in chemical (sterile, noninfectious), autoimmune, and infectious pleuritis, colitis, pancreatitis, and other conditions 13, 14 . Interestingly, hypersecretion of CSF due to CPE hyperplasia or choroid plexus tumors is sufficient to cause non-obstructive hydrocephalus 5 ; however, the impact of IVH on CSF secretion from the CPE has not been studied.
We hypothesized that IVH-induced CPE inflammation might contribute to the development of PHH by increasing the rate of CSF secretion by the CPE. To test this hypothesis, we first assessed CPE inflammation after experimental simulation of IVH in an established rat model of PHH 15 , in which IVH was induced by ICV injection of sterile, lipopolysaccharide (LPS)-free autologous blood into male Wistar rats aged 8 weeks. Control rats received ICV injection of sterile artificial CSF (aCSF) 15 . Rats with experimental PHH developed ventriculomegaly by 48 h after ICV injection, and their CPE cells showed significant activation of NF-κB signaling, as demonstrated by elevated nuclear translocation of p65, a subunit of the NF-κB-p65 transcription complex (Supplementary Fig. 1 ). This was accompanied by increased numbers of activated CD68 + choroid plexus myeloid cells (detected using monoclonal ED-1 antibody) 15 as compared to control rats ( Supplementary Fig. 1a,b) . Intraperitoneal (i.p.) delivery of the NF-κB inhibitor ammonium pyrrolidinedithiocarbamate (PDTC) 16 lowered IVH-associated increases in p65 nuclear translocation and the abundance of CD68 + cells (Supplementary Fig. 1c) . Immunohistochemical (IHC) analysis of the CPE showed increased expression of NF-κB-p65 and the NF-κB-dependent proteins tumor necrosis factor (TNF)-α and CD68 (as indicated by ED-1 labeling) in rats with IVH as compared to controls at 48 h and 7 d after injury (Supplementary Fig. 2 ). In accordance with previous reports 6, 15 , these results demonstrate that IVH triggers CPE inflammation, which is dependent on NF-κB activation.
We next evaluated the effect of IVH on the rate of CSF secretion by the lateral ventricle CPE using a recently developed method for direct measurement in live rats (Fig. 1) 17 . In this method, mineral oil is used to block CSF exit from the third ventricle at the level of the sylvian aqueduct (Fig. 1a) . These conditions prevent contributions to measured CSF production from CSF reabsorption pathways distal to this block, including from glymphatic pathways or arachnoid granulations near the superior sagittal sinus. Therefore, this technique measures bona fide lateral ventricle CSF production (LVCP) by the CPE, as demonstrated previously 17 . At 48 h after ICV injection of blood, LVCP in rats occurred at a rate of ~1.40 ± 0.07 µl/min, which was a nearly threefold greater rate than that in either naive rats or sham-operated controls (~0.50 ± 0.05 (s.e.m.) µl/min; P < 0.01; Fig. 1b) . The LVCP rate peaked at 24 h after IVH and remained elevated at 7 d following IVH (Fig. 1b) . This increase in LVCP rate was associated with significant ventriculomegaly (ventricular volume of ~2.45 ± 0.05 mm 3 in controls versus ~5.40 ± 0.70 mm 3 in rats with IVH; P < 0.01; Fig. 1c,d) . Infusion of aCSF into the lateral ventricles of naive rats at a rate of 1 µl/min for 8 h, approximating the difference in LVCP between IVH and control rats (Fig. 1c,d) , recapitulated the ventriculomegaly seen after IVH (ventricular volume of ~4.90 ± 0.40 mm 3 ; P < 0.05 as compared to controls, P > 0.05 as compared to rats with IVH; Fig. 1c,d ). These data show that IVH causes a significant increase in the CSF secretion rate that is sufficient to cause acute PHH.
Ion and water transport molecules expressed on the apical and basolateral membranes of the CPE mediate CSF secretion via the vectorial transport of Na + , Cl − , and HCO 3 − from blood into the ventricles, which is accompanied by K + recycling across the apical CPE membrane 18 .
We investigated the molecular determinants of IVH-induced CSF hypersecretion. ICV delivery of acetazolamide to inhibit carbonic anhydrase (CA) isoforms that regenerate HCO 3 − only mildly lowered the rate of IVH-induced CSF secretion (Fig. 1e) . Systemic administration of PDTC to inhibit NF-κB signaling decreased both the CSF secretion rate and ventriculomegaly after IVH (CSF secretion rate: ~45% reduction, P < 0.01 (Fig. 1e) ; ventriculomegaly: ~55% decrease in ventricular volume, P < 0.01 (Fig. 2g) ). ICV (but not systemic) delivery of bumetanide, an inhibitor of the Na + -K + -Cl − co-transporter NKCC1, significantly reduced the post-IVH CSH secretion rate and ventriculomegaly (CSF secretion rate: ~80% reduction at 48 h and ~70% reduction at 7 d, P < 0.01 (Fig. 1f,g) ; ventriculomegaly: ~50% reduction in ventricular volume at 48 h, P < 0.01 (Fig. 1g) ). These results demonstrate that CSF hypersecretion after IVH is sensitive to inhibitors of inflammation (PDTC) and NKCC1-dependent ion transport. We evaluated the expression of specific CPE ion transporter polypeptides in the presence and absence of IVH using western blotting of CPE homogenates fractionated by SDS-PAGE. IVH significantly increased the levels of functional NKCC1, detected as pNKCC1 (the active, ion-transporting species phosphorylated at residues Thr203, Thr207, and Thr212) 19 (~6.8-fold increase in activation, P < 0.01; Fig. 2a,b) . In contrast, protein expression of aquaporin-1 (AQP1) and the Na + /K + ATPase (including Na + /K + ATPase phosphorylated at Ser23, pNa + /K + ATPase) was mildly decreased (P < 0.05) in the setting of IVH (Fig. 2a,b) .
In other cell types, the conserved C-terminal domain (CCT) of the serine-threonine STE20/SPS1-related, proline-alanine-rich kinase (SPAK) associates with the (R/K)FX(V/I) motif in NKCC1 and phosphorylates its N terminus at Thr203, Thr207, and Thr212 (ref. 20) . Like other STE20-type kinases that serve as MAP4Ks, SPAK integrates and transduces environmental stress signals 20 , including NF-κB-dependent inflammatory signals 21, 22 . Given the IVH-induced increase in both NKCC1 phosphorylation (at Thr203, Thr207, and Thr212) and bumetanide-sensitive CSF secretion, we tested the effect of IVH on SPAK expression using antibodies specific to the total and phosphorylated forms of the protein on CPE homogenates (Fig. 2a,b) . As for NKCC1, IVH significantly increased the levels of functional SPAK (SPAK phosphorylated at Ser373, pSPAK) by more than twofold relative to levels in control animals (P < 0.01; Fig. 2a,b) .
Reciprocal coimmunoprecipitation experiments with CPE homogenates using antibodies specific to total and phosphorylated SPAK and antibodies specific to NKCC1 each showed that SPAK and NKCC1 form a physical complex in the CPE (Fig. 2c) . This complex included the phosphorylated, active species of both SPAK and NKCC1 (Fig. 2c,d) . The interaction between pSPAK and pNKCC1 was increased in the setting of IVH (Fig. 2c,d ). In accordance with our western blot and coimmunoprecipitation results, IHC analysis of CPE sections labeled with antibodies to pSPAK and pNKCC1 showed a significant increase in pSPAK and pNKCC1 localization to the CPE apical membrane after IVH (Fig. 2e,f) . Treatment with the NF-κB inhibitor PDTC blocked IVHdependent upregulation of the pSPAK-pNKCC1 complex (Fig. 2e,f) .
We applied pharmacological and genetic approaches to test the functional contribution of the pSPAK-pNKCC1 complex to the development of PHH. ICV administration of STOCK1S-50699, which disrupts binding between SPAK and NKCC1 (ref. 23) , restored CSF hypersecretion after IVH to basal levels (CSF secretion rate: reduction of ~50% relative to the rate following IVH, P < 0.01; Fig. 2g) . Closantel, which directly inhibits SPAK kinase activity 24 , restored CSF secretion rates to basal levels and normalized ventricular size after IVH (CSF secretion rate: reduction of ~65% relative to the rate following IVH, P < 0.01 (Fig. 2g) ; ventriculomegaly: ~40%, P < 0.05 (Fig. 2h,i) ). STOCK1S-50699 and closantel were administered either ICV at the time of CSF measurement or ICV via osmotic pump at the time of IVH for ventriculomegaly analysis (Online Methods). ICV delivery of SPAK antisense oligodeoxyribonucleotides (AS-ODNs), but not scrambled control ODNs (Scr-ODNs; Online Methods), decreased levels of both SPAK and pNKCC1 (Supplementary Fig. 3 ) and attenuated IVH-induced CSF hypersecretion (~45% reduction compared to control scrambled ODNs, P < 0.01; Fig. 2g ). These data show that chemical or genetic inhibition of the SPAK-NKCC1 complex attenuates IVH-induced CSF hypersecretion and ventriculomegaly.
We next explored the upstream mechanisms mediating CPE inflammation and upregulation of the pSPAK-pNKCC1 complex after IVH. TLR4-NF-κB signaling is a critical mediator of the innate immune response to bacteria-derived LPS 25 but is also activated by other hostderived 'alarmins' or damage-associated molecular patterns (DAMPs), including sterile blood metabolites 26 . TLR4 is expressed in CPE cells 27 , but the role for TLRs in the pathogenesis of PHH is unclear. We tested the effect of TLR4 inhibition on IVH-induced upregulation of the pSPAK-pNKCC1 complex using the specific TLR4 inhibitor TAK-242 (ref. 28) (Fig. 3a,e) and TLR4-knockout rats (Fig. 3b,f) .
IVH activated TLR4 signaling, as evidenced by upregulation of TAK1 phosphorylation at Thr187 (~2-fold increase, P < 0.05), NF-κB-p65 (up to a 9-fold increase, P < 0.05), and pNF-κB-p65 (NF-κB-p65 phosphorylated at Ser536) (>90-fold increase, P < 0.05) at 24 h and 48 h after IVH and to a lesser extent at 7 d after IVH (Fig. 3d-f) . These changes were accompanied by increased levels of pSPAK (~2-fold, P < 0.01) and pNKCC1 (~6-fold, P < 0.01) (Fig. 3a,c) . TAK-242 abrogated IVH-induced activation of TLR4 signaling and activating phosphorylation of both SPAK (P < 0.01) and NKCC1 (P < 0.01) (Fig. 3a,e) . TLR4 knockout also abolished IVH-induced activation of TLR4 signaling and upregulation of pSPAK (P < 0.01) and pNKCC1 (P < 0.01) (Fig. 3b,f) . In contrast, expression levels of the Na + /K + ATPase and AQP1 were mildly decreased at 24 h after IVH and restored at 7 d after IVH (P < 0.05). We next assessed the role of TLR4 inhibition in IVH-induced CSH hypersecretion using TAK-242 or TLR4-knockout rats (Fig. 3g) . In contrast to the increased rates of CSF secretion measured in rats with wild-type (WT) TLR4 in response to IVH, CSF secretion rates in TLR4-knockout rats were not significantly different from those in control animals (CSF secretion rate: ~70% reduction relative to wildtype, vehicle-treated controls, P < 0.01; Fig. 3g ). In accordance with this finding, TAK-242 also attenuated CSF hypersecretion at 48 h after IVH (CSF secretion rate: ~53% reduction, P < 0.01; Fig. 3g ). These data demonstrate that TLR4 is required for the IVH-induced CSF hypersecretion associated with CPE inflammation.
The data presented here offer several new insights ( Supplementary  Fig. 4) . First, IVH triggers CSF hypersecretion through the CPE, uncovering a previously unrecognized contribution of increased CSF secretion to the pathogenesis of PHH. Second, IVH-induced CPE inflammation and CSF hypersecretion are dependent on TLR4-NF-κB signaling, demonstrating a new role for TLRs in regulation of the internal brain milieu. Third, TLR4-NF-κB signaling stimulates CSF hypersecretion via the SPAK-NKCC1 co-transporter complex, identifying a new kinase-regulated mechanism of CSF secretion.
SPAK is a master regulator of epithelial ion transporters and channels 20 , including the cation-chloride co-transporters 29 . In the nervous system, SPAK is most highly expressed in the CPE, where it localizes to the apical CPE membrane 30 . We showed that SPAK and NKCC1 form a complex in the CPE and that levels of the phosphorylated, active species of each are increased after IVH. Loss of SPAK function in the distal nephron leads to low blood pressure as a result of epithelial NaCl wasting 31 , owing to decreased phosphorylation of the furosemide-sensitive NKCC2, a renal-specific homolog of NKCC1. We have shown that the opposite phenomenon occurs in PHH. After IVH, gain of SPAK function in the CPE leads to PHH as a result of CSF hypersecretion, owing to increased phosphorylation of the bumetanide-sensitive NKCC1 at threonine residues homologous to those in NKCC2. These findings are consistent with the homology of ion transporters and their regulatory networks in the CPE and nephrons 18 . Elucidation of other ion and water transporters and their regulators that coordinate with NKCC1 to mediate the CSF-hypersecretory response could identify other therapeutic targets.
CSF hypersecretion mediated by the SPAK-NKCC1 complex is dependent on TLR4-NF-κB signaling. SPAK is a signal transducer of environmental and cellular stress signals 20 , including NF-κB-dependent inflammation 21, 22 . Interferon (IFN)-γ (ref. 32 ) and TNF-α (ref. 22) stimulate SPAK signaling in an NF-κB-dependent manner to increase epithelial transport in experimental colitis 32 . SPAK could therefore be well positioned to mediate an epithelial 'pro-secretory response' to inflammation dependent on TLR4-NF-κB signaling. Although CSF hypersecretion from the CPE after IVH may resemble the hypersecretory phenotypes in other inflamed epithelia 13, 14 , it is poorly tolerated given the ventricular system's confinement within the rigid skull, and even small elevations in CSF volume can create fatal increases in ICP.
TLR4 inhibition decreases inflammatory injury and neurological deficits after intraparenchymal hemorrhage 33 , and TLR4 and its downstream pathway components (NF-κB and the NF-κB-dependent cytokines TNF-α and IL-1β) are upregulated in the CPE after IVH 6 . It has been reported that IVH-derived metabolites such as heme 33 and methemoglobin 34 serve as DAMPs that bind and activate TLR4. Our results corroborate these findings and further suggest that specific IVH-derived metabolites may serve as CSF-borne host-derived DAMPs that induce TLR4-NF-κB signaling in the CPE. These findings suggest that post-infectious hydrocephalus (PIH), a devastating complication of meningitis from LPS-producing bacteria, could result from similar TLR4-dependent CSF-hypersecretory mechanisms. Such a mechanistic similarity could be of great importance, as PIH is the most common type of hydrocephalus worldwide (including in the developing world, where neurosurgeons are scarce and the costs of ventriculoperitoneal (VP) shunting are prohibitive) 35 . Future studies of the normal and pathophysiological roles of TLRs in the CPE will represent important areas of investigation. Previous trials have failed to show efficacy of systemically administered furosemide or acetazolamide for the treatment of PHH associated with neonatal germinal matrix hemorrhage 36 . However, furosemide and bumetanide have poor blood-brain barrier (BBB) penetration, and furosemide has substantially lower affinity for NKCC1 than bumetanide 37 . ICV 38 , but not i.p. 39 , delivery of the NKCC1 blocker bumetanide moderately decreases baseline CSF secretion levels in dogs, but bumetanide has not been studied in the context of PHH. We showed that IVH-induced CSF hypersecretion and hydrocephalus are sensitive to ICV but not systemic exposure to bumetanide. This is consistent with the low BBB permeability of bumetanide 37 and the post-IVH increase in the levels of pNKCC1 at the apical CPE membrane.
Notably, individuals with PHH often require acute placement of temporary external ventricular drains or reservoirs to divert CSF and decrease elevated ICP before placement of a permanent in-dwelling VP shunt several weeks later. Although endoscopic cauterization of the CPE has proven effective in some forms of infantile hydrocephalus 40 , that efficacy may come at the expense of other critical and increasingly recognized functions of the CPE, such as immune surveillance, growth factor production, and vitamin homeostasis 1 . In contrast, acute ICV delivery of repurposed drugs targeting either TLR4-NF-κB-dependent inflammation or the SPAK-NKCC1 complex might serve as a novel strategy to avoid permanent shunt dependence while preserving other critical 'nonsecretory' CPE functions.
METHoDS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 41 (bred in accordance with the IACUC protocol at the University of Maryland, Baltimore) aged 8 weeks (220-230 g) were anesthetized (60 mg/kg bodyweight ketamine plus 7.5 mg/kg bodyweight xylazine, i.p.) and allowed to breathe room air spontaneously. Body temperature was maintained at 37 ± 1 °C (Harvard Apparatus) throughout the course of the experiments. Animals in this study were randomly chosen for either control or experimental conditions, the researchers were not blinded, and no animals were excluded.
Model of posthemorrhagic hydrocephalus. IVH was modeled using a modified protocol based on previously described methods 15, 42 . In an anesthetized animal, the tail artery was aseptically cannulated using a flexible catheter (PE-20) preloaded with heparinized saline. The rat was then mounted in a stereotactic apparatus (Stoelting Co.), and a midline scalp incision was made to expose the skull, in which a 1-mm burr hole was made using a high-speed drill over the right lateral ventricle (coordinates, relative to the bregma: x, −0.8 mm; y, −1.7 mm). Approximately 200 µl of blood was then drawn from the tail artery catheter and loaded into a 500-µl syringe (Hamilton), which was then mounted on the stereotactic frame. Under stereotactic guidance, 50 µl of freshly collected autologous blood, free from anticoagulants, was infused into the right lateral ventricle (coordinates, relative to the bregma: x, −0.8 mm; y, −1.7 mm; z, −4.5 mm) over the course of 5 min, and the 26-gauge needle was held in place for an additional 20 min to prevent backflow of blood upon needle removal. Intraventricular infusion of sterile aCSF (Tocris) in the same manner served as the control condition.
Quantification of rates of CSF production. Rates of CSF production were measured using the method we recently published 17 . Briefly, anesthetized rats were mounted on a stereotactic apparatus, and a 1.3-mm burr hole was made over the left lateral ventricle (coordinates, relative to the bregma: x, −0.8 mm; y, −1.7 mm). Next, the rat's head was rotated on the ear-bars by 90° so that it was oriented nose down, and the suboccipital muscles were dissected to the cisterna magna to expose the atlanto-occipital ligament. The ligament was punctured, and a 23-gauge flexible catheter (PE-20) was advanced 5 mm through the foramen of Magendie to the fourth ventricle. Sterile moleculargrade mineral oil (100 µl; Sigma-Aldrich) was infused into the fourth ventricle to occlude the aqueduct of Slyvius, thereby creating a closed system of CSF circulation. With the rat in the same position, a glass capillary tube (CV8010-300; borosilicate; OD, 1 mm; ID, 0.8 mm; length, 30 cm; VitroCom) was advanced through the burr hole into the left lateral ventricle. The volume (V) of CSF that formed at a given time point was calculated as: V (mm 3 ) = π·r 2 ·d, where r is the radius of the capillary tube and d is the distance that CSF traveled within the capillary. The rate of CSF formation (µl/min) could be calculated from the slope of the volume-time relationship. Ventricular volume analysis. Following i.p. injection of pentobarbital, rats were transcardially perfused with ice-cold normal saline followed by 10% neutral-buffered formalin. Brains were dissected, kept in formalin for 24 h at 4 °C and then cryoprotected (30% sucrose). To prevent distortion from cryosectioning and slide mounting, we took high-resolution pictures of serial coronal sections (200 µm apart, 14 levels) while the brain was mounted in the cryostat, using uniform parameters of camera positioning, magnification, and external lighting. Adobe Photoshop was used to obtain a pixel count of the lateral ventricular area in each thick section. Pixels were converted to area in mm 2 , summed over 14 levels, and multiplied by the distance between levels (0.2 mm) to calculate ventricular volume.
Eight-hour aCSF infusion.
In anesthetized naive rats, a 28-gauge cannula from an Alzet brain infusion kit (#1; Durect), with a single spacer to adjust the depth to 4.5 mm, was stereotactically placed in the burr hole over the right lateral ventricle and secured to the skull using cyanoacrylate adhesive. A solution of aCSF was infused at 1 µl/min over the course of 8 h. At the end of the 8 h, the rat was euthanized and transcardially perfused and was processed for ventricular volume analysis as described above.
Immunohistochemistry. Rats were transcardially perfused with ice-cold normal saline followed by 10% neutral-buffered formalin. Brains were dissected and kept in formalin for 24 h before being transferred to a 30% sucrose solution for cryoprotection. Brains were cryosectioned (10-µm slices, coronal), blocked (2% donkey serum + 0.2% Triton X-100 for 1 h at room temperature (RT)) and then incubated overnight at 4 °C with primary antibodies. Sections were washed three times in PBS and incubated for 1 h at RT with secondary antibodies (1:500; Alexa Fluor 488 and Alexa Fluor 555; Invitrogen, Molecular Probes). Sections were coverslipped using a polar mounting medium containing DAPI (Invitrogen) and analyzed with epifluorescence microscopy (Nikon Eclipse 90i, Nikon Instruments). Quantification was performed by ROI using NISElements AR software (Nikon Instruments), and specific signal was defined as >2 times the background signal.
Choroid plexus protein isolation. Buffers. Buffer A contained 50 mM Tris/ HCl, pH 7.5, and 0.1 mM EGTA. Lysis buffer contained 50 mM Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% NP-40, 0.27 M sucrose, 0.1% 2-mercaptoethanol, and protease inhibitors (1 tablet per 50 ml). TBS-Tween buffer (TTBS) contained Tris/HCl, pH 7.5, 0.15 M NaCl, and 0.2% Tween-20. SDS sample buffer was 1× NuPAGE LDS sample buffer (Invitrogen) containing 1% 2-mercaptoethanol.
Isolation. Choroid plexuses were dissected rapidly from adult rat brains following transcardial perfusion with ice-cold saline. The brain was isolated and then placed in an ice-cold saline bath, after which the choroid plexus was carefully dissected under magnification using sharp forceps. Approximately 3 mg of choroid plexus tissue was isolated from one brain and was then collected in a 1.5-ml tube.
Immunoblotting and immunoprecipitation. Clarified lysates of CP membrane fraction (15 µg) in SDS sample buffer were subjected to electrophoresis on polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were incubated for 30 min with TTBS containing 5% skim milk. The membranes were then immunoblotted in 5% skim milk in TTBS with the indicated primary antibodies overnight at 4 °C. Sheep antibodies were used at a concentration of 1-2 µg/ml. Incubation with phospho-specific sheep antibodies was performed in the presence of 10 µg/ml of the unphosphorylated peptide antigen to ensure specificity to the phosphorylated antigens. The blots were then washed six times with TTBS and incubated for 1 h at room temperature with secondary HRP-conjugated antibodies diluted 5,000-fold in 5% skim milk in TTBS. After repeating the washing steps, the signal was detected with enhanced chemiluminescence reagent. Immunoblots were developed using a film automatic processor (SRX-101, Konica Minolta Medical), and films were scanned with 600-dpi resolution on a scanner (PowerLook 1000, UMAX). Figures were generated using Photoshop or Illustrator (Adobe). The relative intensities of immunoblot bands were determined by densitometry with ImageJ software. NKCC1 and SPAK were immunoprecipitated from the indicated cell extracts. 0.2 mg of the indicated clarified cell extract was incubated with 15 µg of the indicated antibody conjugated to 15 µl of Protein G-Sepharose. Incubation occurred for 2 h at 4 °C with gentle agitation, and immunoprecipitates were washed three times with 1 ml of lysis buffer containing 0.15 M NaCl and twice with 1 ml of buffer A. Bound proteins were eluted with 1× LDS sample buffer.
ICV drug treatment. The technique described previously for the administration of ICV drugs while measuring the rate of CSF secretion was used 44 . Briefly, at the time of CSF collection, before rotating the rat's head to a vertical orientation, a 28-gauge cannula from an Alzet brain infusion kit (#1; Durect), with a single spacer to adjust the depth to 4.5 mm, was stereotactically placed in the burr hole over the right lateral ventricle and secured to the skull using cyanoacrylate adhesive. The cannula was connected via a preloaded PE-20 catheter to a 1-ml syringe containing the drug solution (see below).
The syringe was loaded into a syringe infusion apparatus (Pump elite 11, Harvard Apparatus) and maintained at 37 °C. To determine the rate of CSF formation during intraventricular drug infusion, the 'actual infusion rate' of the drug (1.93 µl/min) was subtracted from the 'measured outflow rate' to obtain the operational 'calculated rate of CSF formation' . To assess the effect of a drug, the baseline rate of CSF formation was determined during spontaneous CSF formation (no drug infusion), and the calculated rate of formation was then determined after switching to the test drug. Percent change (∆%) was determined using the formula ∆ = − % ( ) ( ) . calculated rate baseline rate baseline rate Intraventricular infusion solutions were made using aCSF, composed as follows (in mM): sodium, 150; potassium, 3.0; calcium, 1.4; magnesium, 0.8; phosphorus, 1.0; chlorine, 155, pH 7.19 (Tocris), with a calculated osmolarity of 311.2 mOsmC/l. The following drugs were used: acetazolamide (45 mM, pH 9; SigmaAldrich), STOCK-1S 50699 (100 µM, pH 6, 1% DMSO), closantel (30 µM, pH 7.2, 0.1% DMSO; Sigma-Aldrich) and bumetanide (2.7 mM, pH 9; SigmaAldrich). Owing to differences in drug solubility, each drug had a specific vehicle control to account for pH, DMSO cosolvent, and osmolarity to ensure that these differences did not alter the rate of CSF production. For each control solution, aCSF solution was altered using NaOH and HCl (Sigma-Aldrich) to adjust pH, and mannitol (Sigma-Aldrich) was added to adjust the osmolarity. In each case, the vehicle controls had no statistical effect on the baseline rate of CSF production, and a representative vehicle control is therefore presented in data analysis for simplicity of data presentation.
Systemic PDTC administration. PDTC (100 mg/kg in normal saline, i.p., Sigma-Aldrich) was administered i.p. at the time of IVH surgery and every 8 h thereafter until 48 h following IVH. At 48 h following IVH, rats were either (i) euthanized, transcardially perfused with saline and 10% neutral-buffered formalin, and processed for immunohistochemistry analysis, as described above, or (ii) anesthetized for surgery to allow for measurement of the rate of CSF secretion, as described above.
Systemic bumetanide administration. The efficacy of systemic bumetanide administration was determined by i.v. infusion of bumetanide at the time at which the rate of CSF production was measured. In an anesthetized rat, the internal jugular vein was exposed and catheterized using a PE-20 flexible catheter preloaded with sterile normal saline. The rat was then mounted into a stereotactic frame in the normal manner for the CSF measurement analysis described above. A baseline measurement of the rate of CSF production was calculated for 25 min. After the baseline rate was determined, the saline-filled syringe attached to the jugular catheter was removed and replaced with a bumetanide-loaded syringe (1 mg/ml in pH 9 normal saline), and 1 ml of bumetanide was infused over 1 min. Following bumetanide infusion, CSF measurement was continued for an additional 30 min to detect any changes in the rate of production.
Systemic TAK-242 administration. TAK-242 (ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate) was purchased from Sigma-Aldrich. The concentration of TAK-242 chosen for intravenous administration (1 mg/kg bodyweight/h; pH 7.2; 10% (2-hydroxypropyl)-β-cyclo-dextrin in normal saline; 0.5% DMSO) was based on previous studies demonstrating the half-life 43 and efficacy of the drug [44] [45] [46] at a concentration range of 0.5-1 mg/kg bodyweight in rats. TAK-242 was dissolved in 100% DMSO for stock solutions and diluted with 10% (2-hydroxypropyl)-β-cyclodextrin in normal saline (prewarmed to 37 °C) for working solutions to a final concentration of 0.5% DMSO. TAK-242 solution was loaded into an Alzet osmotic pump (2ML1, Durect). In an anesthetized rat, the internal jugular vein was exposed and catheterized using a PE-20 flexible catheter preloaded with the TAK-242 solution connected to the Alzet pump. The catheter was secured into place, and the pump was implanted subcutaneously on the back. Five days following TAK-242 pump implantation, the rats were anesthetized and subjected to the model of IVH as described above. The TAK-242 treatment continued over the next 48 h, at which point the rat either underwent CSF secretion measurements or the choroid plexus was dissected for western blot analysis.
In vivo knockdown of SPAK. Previously validated SPAK antisense ODNs (Integrated DNA Technologies) were used for in vivo knockdown of SPAK 47 . ODNs were reconstituted in sterile normal saline and diluted to a final concentration of 0.5 µg/µl for ICV injection. All solutions were sterile filtered. The rats received an ICV injection under stereotactic guidance with a 10-µl bolus of either SPAK or scrambled ODN every 12 h starting 24 h before IVH and continuing until 48 h after IVH. The sequences were as follows: SPAK, GG*CT CC*GCC*ATG*ATGC*TGC; scrambled, CGC*TCG*ATCC*AGG*TCA*GCG (where an asterisk denotes the position of locked nucleic acids). To validate the ability of ODNs to knock down SPAK, IHC was used to detect SPAK and pNKCC1 in naive rats and in rats 48 h after IVH treated with either scrambled or anti-SPAK ODN.
Antibodies for IHC. The following primary antibodies were used: rabbit anti-SPAK ( Antibodies for western blot and immunoprecipitation. The following antibodies were raised in sheep and affinity-purified on the appropriate antigen by the Division of Signal Transduction Therapy Unit at the University of Dundee: NKCC1 total antibody (residues 1-288 of human NKCC1, S022D); NKCC1 phospho-Thr203/Thr207/Thr212 antibody (residues 198-217 of human NKCC1 phosphorylated at Thr203, Thr207 and Thr212, HYYYD(T) HTN(T)YYLR(T)FGHNT, S763B); SPAK mouse antibody (residues 2-76 of mouse SPAK, S668D); SPAK/OSR1 (S motif) phospho-Ser373/Ser325 antibody (residues 367-379 of human SPAK, RRVPGS(S)GHLHKT, which is highly similar to residues 319-331 of human OSR1 in which the sequence is RRVPGS(S)GRLHKT, S670B). β-actin (8H10D10) mouse antibody, phospho-NF-κB p65 (Ser536) antibody (3031), NF-κB p65 (D14E12) antibody (8242), Na + /K + ATPase antibody (3010) and phospho-Na + /K + ATPase α1 (Ser23) antibody (4006) were purchased from Cell Signaling Technology. TLR4 antibody (L-14) (sc-16240) and AQP1 antibody (sc-9878) were purchased from Santa Cruz Biotechnology, NF-κB p105/p50 antibody (ab31412), TAK1 (phospho Thr187) antibody (ab192443) and TAK1 antibody (ab25879) were purchased from Abcam. HRP-coupled secondary antibodies for immunoblotting were obtained from Pierce. SPAK and NKCC1 total antibodies and the phosphorylation-site-specific antibodies were coupled with Protein G-Sepharose at a ratio of 1 mg of antibody to 1 ml of beads in the presence of 20 µg/ml lysate to which the corresponding unphosphorylated peptide had been added. 200 µg of clarified cell lysate was incubated with 10 µg of antibody conjugated to 10 µl of Protein G-Sepharose for 2 h at 4 °C with gentle agitation. Beads were washed three times with 1 ml of lysis buffer containing 0.15 M NaCl and twice with 1 ml of wash buffer (50 mM Tris/HCl, pH 7.5, and 0.1 mM EGTA). Bound proteins were eluted with 1× LDS sample buffer (Invitrogen) containing 1% 2-mercaptoethanol. IgG used in control immunoprecipitation experiments was affinity purified from preimmune serum using Protein G-Sepharose. 
